Clinical trials: Diuretics
Acute Decompensated Heart Failure
DORAYA-HF Early Feasibility Study
The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.
- Trial name
- NCT05206422
- Testing
- Doraya Catheter
- Where
- 14 sites in United States
- Volunteers
- 21 people
- Sponsor
- Revamp Medical Inc.
Uncontrolled Hypertension
A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.
This is a Phase IIIb, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of baxdrostat 2mg versus placebo, administered QD orally, on the reduction of ambulatory 24-hour average…
- Trial name
- BaxNoD (NCT07686120)
- Testing
- baxdrostat 2mg
- Where
- 51 sites in China
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Ascites, Liver Cirrhosis
Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Primary To evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the recurrence of ascites. Secondary To evaluate the tolerability and safety of satavaptan on top of diuretic drugs over a 52-week treatment…
- Trial name
- SPARe-1 (NCT00359437)
- Testing
- Satavaptan
- Where
- 24 sites in United States, Argentina and 22 more
- Volunteers
- 501 people
- Sponsor
- Sanofi
High Blood Pressure
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
This is an open-label, not controlled, sequential, dose escalation study of 16 weeks' duration. The study is composed of two periods: a 0-2 week optional wash-out period depending on previous antihypertensive treatment(s)…
- Trial name
- ANDROMEDA (NCT01056731)
- Testing
- Aliskiren and HCTZ
- Where
- 7 sites in Venezuela
- Volunteers
- 253 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
This study will assess the efficacy and safety of valsartan/hydrochlorothiazide combination therapy in patients with hypertension not controlled with hydrochlorothiazide monotherapy.
- Trial name
- NCT00277472
- Testing
- Valsartan/Hydrochlorothiazide, HCTZ
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Novartis
Nocturia, Benign Prostatic Hypertrophy (BPH)
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
The purpose of this study is to establish the dose response relationship of VA106483 and nocturnal urine volumes in a population of elderly male subjects with Benign Prostatic Hypertrophy (BPH) who are likely to present with…
- Trial name
- NCT01330927
- Testing
- VA106483
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Vantia Ltd
Nocturia
Efficacy Study of VA106483 in Males With Nocturia.
To investigate the effect of VA106483 on nocturia related clinical outcomes compared to placebo.
- Trial name
- NCT01038843
- Testing
- VA106483
- Where
- 19 sites in United States
- Volunteers
- 152 people
- Sponsor
- Vantia Ltd
Hypertension
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that…
- Trial name
- Darusentan (NCT00389779)
- Testing
- Darusentan, Guanfacine
- Where
- 147 sites in United States, Argentina and 8 more
- Volunteers
- 849 people
- Sponsor
- Gilead Sciences
Essential Arterial Hypertension
Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension
Phase IIIb, randomized, double-blind, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination of losartan / chlorthalidone compared with losartan / hydrochlorothiazide in the treatment of…
- Trial name
- NCT04927299
- Testing
- Losartan/Chlorthalidone in fixed dose, Losartan + hydrochlorothiazide in fixed dose
- Where
- Mexico
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Heart Failure, Congestive, Renal Insufficiency
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
- Trial name
- NCT00159614
- Testing
- KW-3902IV
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Healthy Participants
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants
The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986308 compared to placebo in healthy participants.
- Trial name
- NCT04763226
- Testing
- BMS-986308, Furosemide
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Heart Failure, Acute Decompensated Heart Failure
Feasibility Study to Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance
Evaluation of the safety and efficacy of the ModulHeart System in patients hospitalized with acute decompensated heart failure (ADHF) and diuretic resistance
- Conditions
- Heart Failure, Acute Decompensated Heart Failure, Cardiorenal Syndrome, Heart Failure, Congestive
- Trial name
- NCT06174623
- Testing
- ModulHeart Support
- Where
- 5 sites in Australia, Georgia
- Volunteers
- 5 people
- Sponsor
- Puzzle Medical Devices Inc.
Diabetes Mellitus
Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.
Study examining the effect of different diuretics on fluid retention in diabetics treated with rosiglitazone.
- Trial name
- NCT00306696
- Testing
- Rosiglitazone, spironolactone, hydrochlorothiazide
- Where
- 46 sites in Belgium, Canada and 12 more
- Volunteers
- 388 people
- Sponsor
- GlaxoSmithKline
Hypertension
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the U.S., which means that a doctor cannot…
- Trial name
- Darusentan (NCT00353574)
- Testing
- Darusentan
- Where
- 75 sites in United States, Argentina and 6 more
- Volunteers
- 282 people
- Sponsor
- Gilead Sciences
Essential Arterial Hypertension
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on…
- Trial name
- ATHESA (NCT06608472)
- Testing
- N0877, Benicar HCT ® Tablets 40 mg/25 mg
- Sponsor
- Eurofarma Laboratorios S.A.
Hypertension
Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension
The purpose of the study is to test the efficacy and safety of the combination of Calcium Channel Blockers (CCBs)(of the dihydropyridine class) or Diuretics (of the thiazide class) and olmesartan medoxomil in essential…
- Trial name
- NCT00858702
- Testing
- olmesartan medoxomil and a CCB, olmesartan medoxomil and a diuretic
- Where
- Japan
- Volunteers
- 105 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Ascites, Liver Cirrhosis
Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Primary: To evaluate the efficacy of satavaptan in the absence of concomitant diuretic drugs in reducing the recurrence of ascites.
- Trial name
- SPARe-2 (NCT00366795)
- Testing
- Satavaptan
- Where
- 21 sites in United States, Argentina and 19 more
- Volunteers
- 241 people
- Sponsor
- Sanofi
Hypertension, Blood Pressure, High
Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension
The purpose of this study is to determine if there is greater blood pressure reduction using ramipril or hydrochlorothiazide alone or ramipril and hydrochlorothiazide together.
- Trial name
- NCT00355589
- Testing
- Ramipril and hydrochlorothiazide
- Where
- 60 sites in United States
- Sponsor
- Pfizer
Hypertension
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor…
- Trial name
- Darusentan (NCT00389675)
- Testing
- Darusentan, Guanfacine
- Where
- 99 sites in United States, Argentina and 2 more
- Volunteers
- 661 people
- Sponsor
- Gilead Sciences
Heart Failure, Congestive
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00354458
- Testing
- rolofylline
- Volunteers
- 1,102 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)